<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="128">
  <stage>Registered</stage>
  <submitdate>4/08/2005</submitdate>
  <approvaldate>9/08/2005</approvaldate>
  <actrnumber>ACTRN12605000108617</actrnumber>
  <trial_identification>
    <studytitle>A randomised phase II study of preoperative chemotherapy versus preoperative chemoradiation therapy for resectable carcinoma of the oesophagus and gastro-oesophageal junction</studytitle>
    <scientifictitle>A randomised phase II study of feasability, toxicity and quality of life for patients undergoing preoperative chemotherapy versus preoperative chemoradiation therapy for resectable carcinoma of the oesophagus and gastro-oesophageal junction</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Surgical oesophageal trial</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma of the oesophagus</healthcondition>
    <healthcondition>Gastro-oesophageal junction</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Surgery, preoperative chemotherapy, preoperative chemoradiation therapy.</interventions>
    <comparator>Phase II study comparing 2 treatments, neither an accepted control treatment</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Feasibility</outcome>
      <timepoint>At analysis, 13 months after the last patient is enrolled</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Weeks 1, 4, 6, pre-surgery, post surgery 3 monthly for the first 2 years, 4 monthly in the third year, 6 monthly until 12 months after the last patient is enrolled</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Baseline, pre-surgery and 6 monthly until 12 months after the last patient is enrolled</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>Until 12 months after the last patient is enrolled, ie until June 2008</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Until 12 months after the last patient is enrolled, ie until June 2008</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically proven squamus cell carcinoma or adenocarcinoma of the oesophagus or gastro-oesophageal junction, resectable disease, no evidence of extrathoracic or extragastric spread apart from resectable perigastric or mediastinal nodes, adequate haematological &amp; renal function, no previous radiation to the chest, no evidence of tracheo or broncho oesophageal fistula, written informed consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes</concealment>
    <sequence>Random numbers generated with Statview software n=100, no restrictions used.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>12/01/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Associate Professor Bryan Burmeister</primarysponsorname>
    <primarysponsoraddress>Cancer Services Executive, Wing C, Level 2, Building 1, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Associate Professor Mark Smithers</sponsorname>
      <sponsoraddress>GIAST Clinic, Mater Medical Centre, 293 Vulture Stm South Brisbane 4101</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Euan Walpole</sponsorname>
      <sponsoraddress>Cancer Services Executive, Wing C, Level 2, Building 1, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba 4102</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Private Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janine Thomas</name>
      <address>GIAST Clinic, Mater Medical Centre, 293 Vulture Stm South Brisbane 4101</address>
      <phone>07 3844 8500</phone>
      <fax>07 3844 8511</fax>
      <email>janine1972@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Bryan Burmeister</name>
      <address>Radiation Oncology
Princess Alexandra Hospital
Ipswich Rd
Woolloongabba Brisbane QLD 4102</address>
      <phone>+61 7 32406581</phone>
      <fax>+61 7 32402252</fax>
      <email>bryan_burmeister@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>